Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
Takayuki Kobayashi, who has assumed the newly created post of minister in charge of economic security, expressed his determination on October 5 to work towards augmenting Japan’s vaccine development and manufacturing regimes in collaboration with relevant ministries and agencies. The…
To read the full story
Related Article
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
September 30, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…